Amgen Inc.

Xencor, Inc.

Christopher Murawsky

Yang Li

Neeraj Jagdish Agrawal

Ian Nevin Foltz

Zhulun Wang

Xiaoshan Min

Murielle M Veniant-Ellison

Darren L Bates

Donghui Shi

Junming Yie

David J Lloyd

Jinghong Wang

Renee Komorowski

Brandon C P Clavette

Shu-yin Ho

Glenn N Sivits, Jr

Peter Coward

Paul Nioi

Gregory L Moore

Derek Evan Piper

Kevin Graham

Jed Wiltzius

Lawren Wu

Jennitte LeAnn Stevens

Ruben Alvarez Rodriguez

Brian Mingtung Chan

Benjamin M Alba

Jun Zhang

Olivier Nolan-Stevaux

Ryan B Case

Melissa Thomas

Michael John Giffin

Jun Feng

Cong Li

Fernando Garces

Antigen binding proteins that interact with ASGR, ASGR-1 and/or ASGR-2 are described as well as methods of making and using such antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of ASGR, ASGR-1 and/or ASGR-2 antigen binding proteins. Methods of treating and preventing cardiovascular disease by administering a pharmaceutically effective amount of interfering RNA compositions that reduce expression of ASGR, ASGR-1 and/or ASGR-2 are described.

Anti-ASGR-1 monoclonal inhibitory antibodies

Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.

Nucleic acid molecules encoding binding proteins for gastric inhibitory peptide receptor (GIPR)

Antigen binding molecules, chimeric receptors, and engineered immune cells to DLL3 are disclosed in accordance with the invention. The invention further relates to vectors, compositions, and methods of treatment and/or detection using the DLL3 antigen binding molecules and engineered immune cells.

Chimeric receptors to DLL3 and methods of use thereof

The disclosure provides novel antigen-binding proteins that bind STEAP1 and methods of use.

Anti-STEAP1 antigen-binding protein

Methods of treating cardiovascular disease with an anti-ASGR antibody or binding fragments thereof

Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists

Growing community of inventors

Roberts Creek, Canada

Christopher Murawsky